SLC5A2 and hydrops fetalis: In addition to blood glucose lowering, SGLT2 inhibitors have been shown to reduce atherosclerosis-related events, hospitalizations for heart failure (HF), and cardiovascular as well as all-cause mortality [8,9,10,11,12,13].